Anavex Life Sciences Corp (AVXL)

[Investor2014]

Of course. The important thing here is an emphasis on merits, as opposed to the many previous phase 3 trials that failed because they did not analyse their phase 2 data properly. In fact they could only do post hoc subgroup analysis because their trial design was not adaptive.

You see, medicine is tricky!